23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › SAREPTA THERAPEUTICS INC. › 2023-2024

SAREPTA THERAPEUTICS INC. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and SAREPTA THERAPEUTICS INC.’s Form 8-K, filed June 7, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 6Ballot items
  • 427Asset managers, any item
  • 3,109Fund votes
  • June 6, 2024Meeting date

Results at a glance

Meeting of June 6, 2024: 6 items on SAREPTA THERAPEUTICS INC.’s Form 8-K, filed June 7, 2024: 4 elected · 2 approved.

Dissent

Notable dissent: 1 director (14.3% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore SAREPTA THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by SAREPTA THERAPEUTICS INC.

These tallies are SAREPTA THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 7, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

SAREPTA THERAPEUTICS INC. — official shareholder meeting results, meeting held June 6, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Douglas S. Ingram 71,684,0031,141,80516,569 --8,161,580 98%Elected—
Elect Director: Hans Wigzell, M.D., Ph.D. 62,357,68310,424,42260,272 --8,161,580 86%Elected—
Elect Director: Kathryn J. Boor, Ph.D. 66,169,6556,656,36716,355 --8,161,580 91%Elected—
Elect Director: Michael Chambers 71,087,1551,737,71517,507 --8,161,580 98%Elected—
2. Advisory Vote to Approve Named Executive Officer Compensation 63,631,1979,004,619206,561 --8,161,580 88%Approved—
3. Ratification of KPMG as the Company's Independent Registered Public Accounting Firm 77,132,5483,758,836112,573 ---- 95%Approved—

Source: SAREPTA THERAPEUTICS INC., Form 8-K, filed with the SEC on June 7, 2024 — read the filing on EDGAR.

How asset managers voted at the SAREPTA THERAPEUTICS INC. 2023-2024 meeting

427 asset managers disclosed a vote on at least one SAREPTA THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Douglas S. Ingram

Official resultFund totals may overlapDIRECTOR ELECTIONSReported outcome: Elected

Combines 6 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 71,684,003AGAINST: 1,141,805
Details: description as filed, official tally, votes by 118 asset managers

Description as filed by funds: to elect, as Class I directors to hold office until 2026 annual meeting of stockholders, or until their successors are earlier elected, the following director nominees: Douglas S. Ingram

SAREPTA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Douglas S. Ingram”): 71,684,003 for, 1,141,805 against, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The director nominees listed below were elected to serve on the Company's board of directors as members of Class I for a term of two years.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 112 asset managers voting on “to elect, as Class I directors to hold office until 2026 annual meeting of stockholders, or until their succes” at SAREPTA THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard10,724,2180 00For
Capital Group3,220,3740 00For
Fidelity3,027,7570 00For
JANUS INVESTMENT FUND2,936,5410 00For
BlackRock2,487,5980 00For
AMCAP FUND1,540,0790 00For
T. Rowe Price1,404,4460 00For
BNY Mellon784,6640 00For
JPMorgan712,6750 00For
State Street649,562961 00For
Federated Hermes609,1750 00For
Thrivent597,4570 00For
Charles Schwab587,1190 00For
Hartford549,2060 00For
TIAA514,0690 00For
Jackson National322,2570 00For
Aberdeen191,8570 00For
Voya165,2650 00For
Allspring162,8200 00For
CARILLON SERIES TRUST155,3260 00For
Equitable147,8740 00For
Columbia Threadneedle147,7370 00For
Dimensional140,1070 00For
MUTUAL FUND SERIES TRUST135,7300 00For
AIG/SunAmerica123,6900 00For

Fund voting reports, all 112 managers: 34,260,072 for, 963 against, 3,543 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 6 asset managers voting on “to elect, as Class I directors to hold office until 2026 annual meeting of stockholders, or until their succes” at SAREPTA THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Erste Asset Management GmbH571,4000 00For
HOWLAND CAPITAL MANAGEMENT LLC1,6320 00For
Evernest Financial Advisors, LLC1610 00For
Boltwood Capital Management250 00For
Keel Point, LLC160 00For
Warren Street Wealth Advisors, LLC120 00For

Institutional-manager reports, all 6 managers: 573,246 for.

Elect Director: Hans Wigzell, M.D., Ph.D.

Official resultFund totals may overlapDIRECTOR ELECTIONSReported outcome: Elected

Combines 8 wordings of this item as funds reported it.

86% Majority: yes · of votes cast

FOR 86%AGAINST
FOR: 62,357,683AGAINST: 10,424,422
Details: description as filed, official tally, votes by 118 asset managers

Description as filed by funds: to elect, as Class I directors to hold office until 2026 annual meeting of stockholders, or until their successors are earlier elected, the following director nominees: Hans Wigzell, M.D., Ph.D.

SAREPTA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Hans Wigzell, M.D., Ph.D.”): 62,357,683 for, 10,424,422 against, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The director nominees listed below were elected to serve on the Company's board of directors as members of Class I for a term of two years.”
Support: 86% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 112 asset managers voting on “to elect, as Class I directors to hold office until 2026 annual meeting of stockholders, or until their succes” at SAREPTA THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard10,724,2180 00For
Capital Group3,220,3740 00For
Fidelity3,020,4357,322 00For
JANUS INVESTMENT FUND2,936,5410 00For
BlackRock2,487,5980 00For
AMCAP FUND1,540,0790 00For
T. Rowe Price01,404,446 00Against
BNY Mellon784,6640 00For
JPMorgan712,6750 00For
State Street13,036637,487 00Against
Federated Hermes609,1750 00For
Thrivent597,4570 00For
Charles Schwab587,1190 00For
Hartford549,2060 00For
TIAA514,0690 00For
Jackson National162,613159,644 00Mixed
Aberdeen191,8570 00For
Voya165,2650 00For
Allspring162,8200 00For
CARILLON SERIES TRUST155,3260 00For
Equitable82,18565,689 00Mixed
Columbia Threadneedle0147,737 00Against
Dimensional140,1070 00For
MUTUAL FUND SERIES TRUST135,7300 00For
AIG/SunAmerica123,6900 00For

Fund voting reports, all 112 managers: 31,091,409 for, 3,169,626 against, 3,543 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 6 asset managers voting on “to elect, as Class I directors to hold office until 2026 annual meeting of stockholders, or until their succes” at SAREPTA THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Erste Asset Management GmbH571,4000 00For
HOWLAND CAPITAL MANAGEMENT LLC1,6320 00For
Evernest Financial Advisors, LLC1610 00For
Boltwood Capital Management250 00For
Keel Point, LLC160 00For
Warren Street Wealth Advisors, LLC120 00For

Institutional-manager reports, all 6 managers: 573,246 for.

Elect Director: Kathryn J. Boor, Ph.D.

Official resultFund totals may overlapDIRECTOR ELECTIONSReported outcome: Elected

Combines 7 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%
FOR: 66,169,655AGAINST: 6,656,367
Details: description as filed, official tally, votes by 118 asset managers

Description as filed by funds: to elect, as Class I directors to hold office until 2026 annual meeting of stockholders, or until their successors are earlier elected, the following director nominees: Kathryn J. Boor, Ph.D.

SAREPTA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Kathryn J. Boor, Ph.D.”): 66,169,655 for, 6,656,367 against, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The director nominees listed below were elected to serve on the Company's board of directors as members of Class I for a term of two years.”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 112 asset managers voting on “to elect, as Class I directors to hold office until 2026 annual meeting of stockholders, or until their succes” at SAREPTA THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard10,724,2180 00For
Capital Group3,220,3740 00For
Fidelity3,020,4357,322 00For
JANUS INVESTMENT FUND2,936,5410 00For
BlackRock2,487,5980 00For
AMCAP FUND1,540,0790 00For
T. Rowe Price01,404,446 00Against
BNY Mellon784,6640 00For
JPMorgan712,6750 00For
State Street649,0541,469 00For
Federated Hermes609,1750 00For
Thrivent597,4570 00For
Charles Schwab587,1190 00For
Hartford549,2060 00For
TIAA514,0690 00For
Jackson National162,613159,644 00Mixed
Aberdeen191,8570 00For
Voya165,2650 00For
Allspring162,8200 00For
CARILLON SERIES TRUST155,3260 00For
Equitable82,18565,689 00Mixed
Columbia Threadneedle147,7370 00For
Dimensional140,1070 00For
MUTUAL FUND SERIES TRUST135,7300 00For
AIG/SunAmerica123,6900 00For

Fund voting reports, all 112 managers: 31,942,195 for, 2,318,840 against, 3,543 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 6 asset managers voting on “to elect, as Class I directors to hold office until 2026 annual meeting of stockholders, or until their succes” at SAREPTA THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Erste Asset Management GmbH571,4000 00For
HOWLAND CAPITAL MANAGEMENT LLC1,6320 00For
Evernest Financial Advisors, LLC1610 00For
Boltwood Capital Management250 00For
Keel Point, LLC160 00For
Warren Street Wealth Advisors, LLC120 00For

Institutional-manager reports, all 6 managers: 573,246 for.

Elect Director: Michael Chambers

Official resultFund totals may overlapDIRECTOR ELECTIONSReported outcome: Elected

Combines 8 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 71,087,155AGAINST: 1,737,715
Details: description as filed, official tally, votes by 118 asset managers

Description as filed by funds: to elect, as Class I directors to hold office until 2026 annual meeting of stockholders, or until their successors are earlier elected, the following director nominees: Michael Chambers

SAREPTA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Michael Chambers”): 71,087,155 for, 1,737,715 against, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The director nominees listed below were elected to serve on the Company's board of directors as members of Class I for a term of two years.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 112 asset managers voting on “to elect, as Class I directors to hold office until 2026 annual meeting of stockholders, or until their succes” at SAREPTA THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard10,724,2180 00For
Capital Group3,220,3740 00For
Fidelity3,020,4357,322 00For
JANUS INVESTMENT FUND2,936,5410 00For
BlackRock2,487,5980 00For
AMCAP FUND1,540,0790 00For
T. Rowe Price1,064,377340,069 00Mixed
BNY Mellon784,6640 00For
JPMorgan712,6750 00For
State Street649,835688 00For
Federated Hermes609,1750 00For
Thrivent597,4570 00For
Charles Schwab587,1190 00For
Hartford549,2060 00For
TIAA514,0690 00For
Jackson National322,2570 00For
Aberdeen191,8570 00For
Voya165,2650 00For
Allspring162,8200 00For
CARILLON SERIES TRUST155,3260 00For
Equitable82,18565,689 00Mixed
Columbia Threadneedle147,7370 00For
Dimensional140,1070 00For
MUTUAL FUND SERIES TRUST135,7300 00For
AIG/SunAmerica123,6900 00For

Fund voting reports, all 112 managers: 33,698,911 for, 562,124 against, 3,543 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 6 asset managers voting on “to elect, as Class I directors to hold office until 2026 annual meeting of stockholders, or until their succes” at SAREPTA THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Erste Asset Management GmbH571,4000 00For
HOWLAND CAPITAL MANAGEMENT LLC1,6320 00For
Evernest Financial Advisors, LLC1610 00For
Boltwood Capital Management250 00For
Keel Point, LLC160 00For
Warren Street Wealth Advisors, LLC120 00For

Institutional-manager reports, all 6 managers: 573,246 for.

Advisory Vote to Approve Named Executive Officer Compensation

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 19 wordings of this item as funds reported it.

88% Approved · of votes cast

FOR 88%
FOR: 63,631,197AGAINST: 9,004,619

Prior year: 27.9% for (June 8, 2023 meeting) ▲ 59.7 pts

Details: description as filed, official tally, votes by 424 asset managers

Description as filed by funds: advisory vote to approve, on a non-binding basis, named executive officer compensation

SAREPTA THERAPEUTICS INC.’s own tally for this item (“2. Advisory Vote to Approve Named Executive Officer Compensation”): 63,631,197 for, 9,004,619 against — passed, per its Form 8-K filed June 7, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2: Advisory Vote to Approve Named Executive Officer Compensation The stockholders approved, on an advisory basis, the compensation of the Company's named executive officers for 2023.”
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 114 asset managers voting on “advisory vote to approve, on a non-binding basis, named executive officer compensation” at SAREPTA THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard10,724,2180 00For
Capital Group3,220,3740 00For
Fidelity3,027,7570 00For
JANUS INVESTMENT FUND2,936,5410 00For
BlackRock2,487,5980 00For
AMCAP FUND1,540,0790 00For
T. Rowe Price1,404,4460 00For
BNY Mellon784,6640 00For
JPMorgan712,6750 00For
State Street650,5230 00For
Federated Hermes609,1750 00For
Thrivent597,4570 00For
Charles Schwab587,1190 00For
Hartford549,2060 00For
TIAA514,0690 00For
Jackson National321,0551,202 00For
Aberdeen191,8570 00For
Voya165,2650 00For
Allspring162,8200 00For
CARILLON SERIES TRUST155,3260 00For
Equitable147,8740 00For
Columbia Threadneedle147,7370 00For
Dimensional0140,107 00Against
MUTUAL FUND SERIES TRUST135,7300 00For
AIG/SunAmerica123,6900 00For

Fund voting reports, all 114 managers: 33,806,961 for, 553,205 against, 2,144 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 339 asset managers voting on “advisory vote to approve, on a non-binding basis, named executive officer compensation” at SAREPTA THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
OAK RIDGE INVESTMENTS LLC17,000,0000 00For
Capital Group4,818,0720 00For
Janus Henderson4,781,4470 00For
Avoro Capital Advisors LLC3,487,8940 00For
Wellington3,137,8720 00For
BlackRock2,769,4391,064 00For
FARALLON CAPITAL MANAGEMENT LLC02,437,500 00Against
T. Rowe Price2,426,6610 00For
EcoR1 Capital, LLC1,919,8350 00For
State Street1,911,2800 00For
JPMorgan1,739,7860 00For
GEODE CAPITAL MANAGEMENT, LLC1,519,6150 00For
Fidelity1,348,8430 00For
Newton Investment Management North America, LLC1,033,1510 00For
PICTET ASSET MANAGEMENT SA928,5370 00For
BNY Mellon647,1330 00For
ORBIMED ADVISORS LLC0610,500 00Against
Federated Hermes609,1880 00For
Thrivent606,7350 00For
Charles Schwab590,1540 00For
Camber Capital Management LP585,0000 00For
Erste Asset Management GmbH571,4000 00For
Nuveen542,0590 00For
Paradigm Biocapital Advisors LP540,9020 00For
ADAGE CAPITAL PARTNERS GP, L.L.C.470,0000 00For

Institutional-manager reports, all 339 managers: 61,549,404 for, 5,992,887 against, 159,604 abstained, 1,189 not voted, 8 unknown. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of KPMG as the Company's Independent Registered Public Accounting Firm

Official resultFund totals may overlapAUDIT-RELATEDReported outcome: Approved

Combines 7 wordings of this item as funds reported it.

95% Approved · of votes cast

FOR 95%
FOR: 77,132,548AGAINST: 3,758,836

Prior year: 97.9% for (June 8, 2023 meeting) ▼ 2.5 pts

Details: description as filed, official tally, votes by 120 asset managers

Description as filed by funds: ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the current year ending December 31, 2024

SAREPTA THERAPEUTICS INC.’s own tally for this item (“3. Ratification of KPMG as the Company's Independent Registered Public Accounting Firm”): 77,132,548 for, 3,758,836 against — passed, per its Form 8-K filed June 7, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3: Ratification of KPMG as the Company's Independent Registered Public Accounting Firm The stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ended December 31, 2024.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 114 asset managers voting on “ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the curren” at SAREPTA THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard10,724,2180 00For
Capital Group3,220,3740 00For
Fidelity3,027,7570 00For
JANUS INVESTMENT FUND2,936,5410 00For
BlackRock2,487,5980 00For
AMCAP FUND1,540,0790 00For
T. Rowe Price1,404,4460 00For
BNY Mellon784,6640 00For
JPMorgan712,6750 00For
State Street648,0032,520 00For
Federated Hermes609,1750 00For
Thrivent597,4570 00For
Charles Schwab587,1190 00For
Hartford549,2060 00For
TIAA514,0690 00For
Jackson National322,2570 00For
Aberdeen191,8570 00For
Voya165,2650 00For
Allspring162,8200 00For
CARILLON SERIES TRUST155,3260 00For
Equitable147,8740 00For
Columbia Threadneedle147,7370 00For
Dimensional140,1070 00For
MUTUAL FUND SERIES TRUST135,7300 00For
AIG/SunAmerica123,6900 00For

Fund voting reports, all 114 managers: 34,134,901 for, 225,265 against, 2,144 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 6 asset managers voting on “ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the curren” at SAREPTA THERAPEUTICS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Erste Asset Management GmbH571,4000 00For
HOWLAND CAPITAL MANAGEMENT LLC1,6320 00For
Evernest Financial Advisors, LLC1610 00For
Boltwood Capital Management250 00For
Keel Point, LLC160 00For
Warren Street Wealth Advisors, LLC120 00For

Institutional-manager reports, all 6 managers: 573,246 for.

Largest SAREPTA THERAPEUTICS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 94,490,157 shares outstanding at the time of that meeting.

Fund voting reports: top SAREPTA THERAPEUTICS INC. shareholders by shares voted on “advisory vote to approve, on a non-binding basis, named executive officer compensation”, 2023-2024
#Asset manager % of shares outstanding
1Vanguard 11.35%
2Capital Group 3.41%
3Fidelity 3.20%
4JANUS INVESTMENT FUND 3.11%
5BlackRock 2.63%
6AMCAP FUND 1.63%
7T. Rowe Price 1.49%
8BNY Mellon 0.83%
9JPMorgan 0.75%
10State Street 0.69%
Institutional-manager reports: top SAREPTA THERAPEUTICS INC. shareholders by shares voted on “advisory vote to approve, on a non-binding basis, named executive officer compensation”, 2023-2024
#Asset manager % of shares outstanding
1OAK RIDGE INVESTMENTS LLC 17.99%
2Capital Group 5.10%
3Janus Henderson 5.06%
4Avoro Capital Advisors LLC 3.69%
5Wellington 3.32%
6BlackRock 2.93%
7FARALLON CAPITAL MANAGEMENT LLC 2.58%
8T. Rowe Price 2.57%
9EcoR1 Capital, LLC 2.03%
10State Street 2.02%

Reported SAREPTA THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

SAREPTA THERAPEUTICS INC. holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Shares Issued and Outstanding 3/31/202494,490,157 —Proxy statement (DEF 14A), proxy filed April 24, 2024
BlackRock13,199,845 —Form 13F, quarter ended March 31, 2024
Vanguard Group10,817,446 —Form 13F, quarter ended March 31, 2024
Janus Henderson Group plc, 201 Bishopsgate, London, EC2M 3AE, United Kingdom5,345,785 —Proxy statement (DEF 14A), proxy filed April 24, 2024
Capital International Investors4,741,485 —Proxy statement (DEF 14A), proxy filed April 24, 2024
Wellington Management3,245,798 —Form 13F, quarter ended March 31, 2024
Richard J. Barry3,238,008 —Proxy statement (DEF 14A), proxy filed April 24, 2024
Douglas Ingram2,590,417 —Proxy statement (DEF 14A), proxy filed April 24, 2024
Citadel Advisors2,133,277 —Form 13F, quarter ended March 31, 2024
State Street2,122,491 —Form 13F, quarter ended March 31, 2024

Percentages above are of 94,490,157 shares outstanding, as reported by SAREPTA THERAPEUTICS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At SAREPTA THERAPEUTICS INC.'s shareholder meeting held June 6, 2024, in the 2023-2024 proxy season, 427 asset managers reported votes on at least one of its 6 ballot items in their SEC Form N-PX filings, covering 3,109 separate fund positions. On the most widely held item on that ballot — advisory vote to approve, on a non-binding basis, named executive officer compensation — SAREPTA THERAPEUTICS INC.'s filing reports the proposal as approved, with 88% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: SAREPTA THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 7, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from SAREPTA THERAPEUTICS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

SAREPTA THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Cite this page

Proxy Votes Now, “SAREPTA THERAPEUTICS (SRPT) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/sarepta-therapeutics-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.